Skip to main content
Download PDF

Cancer proteomics

New opportunities for old molecules?

Clinical Proteomics volume 2, pages 129–132 (2006)Cite this article

Conclusion

The future of cancer diagnostics will be based on a panel of proteomic biomarkers. They could be used to detect cancer at an early stage, to predict and to direct therapies. Enzymes and related proteins are important biological molecules, which could serve as cancer biomarkers. These biomarkers could be intact or fragments of proteins. The challenge is to be able to find and validate these potential biomarkers as clinical diagnostics. With the advances in proteomic technologies, we are closer than ever to find these “new” enzyme molecules or fragments. The translation of newly discovered biomarkers could provide an opportunity to revolutionize the era of personalized medicine.

References

  1. Anderson, N. L. and Anderson, N. G. (2002) The human plasma proteome: history, character, and diagnostic prospects.Mol. Cell. Proteomics 1, 845–867.

    Article  PubMed  CAS  Google Scholar 

  2. McDonald, W. H. and Yates, J. R., 3rd. (2002) Shotgun proteomics and biomarker discovery.Dis. Markers 18, 99–105.

    PubMed  CAS  Google Scholar 

  3. Colantonio, D. A. and Chan, D. W. (2005). The clinical application of proteomics.Clin. Chimica. Acta 357, 151–158.

    Article  CAS  Google Scholar 

  4. Tirumalai, R. S., Chan, K. C., Prieto, D. A., Issaq, H. J., Conrads, T. P., and Veenstra, T. D. (2003) Characterization of the low molecular weight human serum proteome.Mol. Cell. Proteomics 2, 1096–1103.

    Article  PubMed  CAS  Google Scholar 

  5. Rodland, K. D. (2004) Proteomics and cancer diagnosis: the potential of mass spectrometry.Clin. Biochem. 37, 579–583.

    Article  PubMed  CAS  Google Scholar 

  6. Zhang, Z. and Chan, D. W. (2005) Cancer proteomics: in pursuit of “true” biomarker discovery.Cancer Epidemiol. Biomarkers Prev. 14, 2283–2286.

    Article  PubMed  CAS  Google Scholar 

  7. Rifai, N., Gillette, M. A., and Carr, S. A. (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility.Nat. Biotechnol. 24, 971–983.

    Article  PubMed  CAS  Google Scholar 

  8. Mikolajczyk, S. D., Millar, L. S., Wang, T. J., et al. (2000) A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.Cancer Res. 60, 756–759.

    PubMed  CAS  Google Scholar 

  9. Chen Z, Chen H, Stamey TA. (1997) Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.J. Urol. 157, 2166–2170.

    Article  PubMed  CAS  Google Scholar 

  10. Mikolajczyk, S. D., Song, Y., Wong, J. R., Matson, R. S., and Rittenhouse, H. G. (2004) Are multiple markers the future of prostate cancer diagnostics?Clin. Biochem. 37, 519–528.

    Article  PubMed  CAS  Google Scholar 

  11. Sokoll, L. J., Chan, D. W., Mikolajczyk, S. D., et al. (2003) Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis.Urology 61, 274–276.

    Article  PubMed  Google Scholar 

  12. Zhang, Z, Bast, R. C., Jr, Yu, Y., et al. (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.Cancer Res. 64, 5882–5890.

    Article  PubMed  CAS  Google Scholar 

  13. Song, J., Patel, M., Rosenzweig, C. N., et al. (2006) Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay.Clin. Chem. 52, 1045–1053.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Johns Hopkins Medical Institutions, Room 3M05, CRB2 Building, 1550 Orleans St., 21231, Baltimore, MD

    Daniel W. Chan & Shu-Ling Liang

Authors
  1. Daniel W. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shu-Ling Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Chan, D.W., Liang, SL. Cancer proteomics. Clin Proteom 2, 129–132 (2006). https://doi.org/10.1007/BF02752495

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02752495

Clinical Proteomics

ISSN: 1559-0275